Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease

GLIA

Volumn 58, Issue 5, 2010, Pages 588-598

  Rojo, Ana I ^a,b   Innamorato, Nadia G ^a,b   Martín Moreno, Ana M ^a,c   De Ceballos, María L ^a,c   Yamamoto, Masayuki ^d   Cuadrado, Antonio ^a,b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c INSTITUTO CAJAL   (Spain)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Heme oxygenase 1; Innate immune system; Neurodegenerative diseases

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ARGINASE 1; CD11B ANTIGEN; CD45 ANTIGEN; CYCLOOXYGENASE 2; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PROTEIN; PROTEIN F4 80; PROTEIN FIZZ 1; PROTEIN YM 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTOSIS; BASAL GANGLION; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; GENE EXPRESSION; MACROPHAGE ACTIVATION; MACROPHAGE MIGRATION; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION; BRAIN; CALCIUM-BINDING PROTEINS; CELL LINE, TRANSFORMED; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MPTP POISONING; NEURONS; NF-E2-RELATED FACTOR 2; NITRIC OXIDE SYNTHASE TYPE II; REACTIVE OXYGEN SPECIES; TYROSINE 3-MONOOXYGENASE;

EID: 77749339881     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20947     Document Type: Article

References (47)

1. Arai H, Furuya T, Mizuno Y, Mochizuki H. 2006. Inflammation and infection in Parkinson's disease. Histol Histopathol 21:673-678.
2. Block ML, Zecca L, Hong JS. 2007. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69.
3. Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW. 2006. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2:249-253.
4. Bowling AC, Beal MF. 1995. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 56:1151-1171.
5. Cassarino DS, Fall CP, Swerdlow RH, Smith TS, Halvorsen EM, Miller SW, Parks JP, Parker WD Jr, Bennett JP Jr. 1997. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim Biophys Acta 1362:77-86.
6. Chen L, Cagniard B, Mathews T, Jones S, Koh HC, Ding Y, Carvey PM, Ling Z, Kang UJ, Zhuang X. 2005. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280:21418-21426.
7. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA. 2009. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc Natl Acad Sci USA 106:2933-2938.
8. Choi HK, Won L, Roback JD, Wainer BH, Heller A. 1992. Specific modulation of dopamine expression in neuronal hybrid cells by primary cells from different brain regions. Proc Natl Acad Sci USA 89:8943-8947.
9. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O. 2002. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-998.
10. Clark J, Simon DK. 2009. Transcribe to Survive: Transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. Antioxid Redox Signal 3:509-528.
11. Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, Finsen B. 2008. Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 5:46.
12. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. 2006. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 103:15091-15096.
13. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. 2006. Expression profiles for macrophage alternative activation genes in AD, in mouse models of AD. J Neuroinflammation 3:27.
14. Cuadrado A, Moreno-Murciano P, Pedraza-Chaverri J. 2009. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. Expert Opin Ther Targets 13:319-329.
15. Dawson TM, Dawson VL. 2003. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822.
16. de Haas AH, Boddeke HW, Brouwer N, Biber K. 2007. Optimized isolation enables ex vivo analysis of microglia from various central nervous system regions. Glia 55:1374-1384.
17. Dick FD, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Mozzoni P, Haites N, Wettinger SB, Mitti A, Otelea M, Seaton A, Soderkvist P, Felice A. 2007. Gene-environment interactions in parkinsonism and Parkinson's disease: The Geoparkinson study. Occup Environ Med 64:673-680.
18. Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF. 2005. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett 375:91-96.
19. Fasano M, Bergamasco B, Lopiano L. 2006. Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 96:909-916.
20. Gao HM, Hong JS. 2008. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol 29:357-365.
21. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. 2006. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404-412.
22. Hirsch EC, Faucheux BA. 1998. Iron metabolism and Parkinson's disease. Mov Disord 13 (Suppl 1):39-45.
23. Hu X, Zhang D, Pang H, Caudle WM, Li Y, Gao H, Liu Y, Qian L, Wilson B, Di Monte DA, Ali SF, Zhang J, Block ML, Hong JS. 2008. Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol 181:7194-7204.
24. Innamorato NG, Rojo AI, Garcia-Yague AJ, Yamamoto M, de Ceballos ML, Cuadrado A. 2008. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181:680-689.
25. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima B. 1997. An Nrf2/small Maf heterodimer mediates the induction of Phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236:313-322.
26. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32 Suppl:S82-S87.
27. Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC. 2008. The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61-69.
28. Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A. 2006. Ibuprofen and the mouse model of Parkinson's disease. Ann Neurol 59:988-989.
29. Kushnareva Y, Murphy AN, Andreyev A. 2002. Complex I-mediated reactive oxygen species generation: Modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem J 368 (Part 2):545-553.
30. Malhotra D, Thimmulappa R, Navas-Acien A, Sandford A, Elliott M, Singh A, Chen L, Zhuang X, Hogg J, Pare P, Tuder RM, Biswal S. 2008. Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 178:592-604.
31. Min KJ, Yang MS, Kim SU, Jou I, Joe EH. 2006. Astrocytes induce hemeoxygenase-1 expression in microglia: A feasible mechanism for preventing excessive brain inflammation. J Neurosci 26:1880-1887.
32. Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28:57-87.
33. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958-969.
34. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. 2007. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 85:919-934.
35. Olanow CW. 2007. The pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord 22 (Suppl 17):S335-S342.
36. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, Kensler TW, Yamamoto M, Petrache I, Tuder RM, Biswal S. 2004. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 114:1248-1259.
37. Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, Yamamoto M, Kensler TW, Tuder RM, Georas SN, Biswal S. 2005. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 202:47-59.
38. Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A. 2006. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J Biol Chem 281:14841-14851.
39. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. 2002. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alphasynuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
40. Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. 2008. Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 312:131-138.
41. Smith PF. 2008. Inflammation in Parkinson's disease: An update. Curr Opin Investig Drugs 9:478-484.
42. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, Biswal S. 2006. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 116:984-995.
43. Westerlund M, Belin AC, Anvret A, Hakansson A, Nissbrandt H, Lind C, Sydow O, Olson L, Galter D. 2009. Association of a polymorphism in the ABCB1 gene with Parkinson's disease. Parkinsonism Relat Disord 15:422-424.
44. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-1771.
45. Zeevalk GD, Razmpour R, Bernard LP. 2008. Glutathione and Parkinson's disease: Is this the elephant in the room? Biomed Pharmacother 62:236-249.
46. Zhou C, Huang Y, Przedborski S. 2008. Oxidative stress in Parkinson's disease: A mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147:93-104.
47. Zhou W, Freed CR. 2005. DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem 280:43150-43158.